MacroGenics, Takeda deal
MacroGenics granted Takeda an option to license exclusive, worldwide rights to four research programs against undisclosed jointly selected targets. The products will be developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology. Takeda will fund R&D and reimburse MacroGenics' expenses. The partners declined to disclose specific indications, but Takeda did say the deal includes autoimmune disorders.
MacroGenics is eligible for up to $400 million in milestones, plus double-digit royalties for each product Takeda exercises its option to license. Additionally, MacroGenics has the option to co-promote each product in the U.S. and may elect to fund a portion of Phase III testing of each product in exchange for an undisclosed North American profit share. ...